鬆齡護老集團(01989.HK)年度核心EBITDA上升81.2%至5820萬港元
格隆匯 6 月 26日丨鬆齡護老集團(01989.HK)公佈年度業績,截至2020年3月31日止年度業績,公司實現收益2.17億港元,同比上升16.37%;母公司擁有人應占年度溢利1358.4萬港元,同比上升1.11%;核心EBITDA上升81.2%至5820萬港元。扣除採納香港財務報告準則第16號的影響後,核心EBITDA上升19.6%至3840萬港元,基本及攤薄每股盈利1.5港仙。
收益增加主要由於以下各項的綜合影響:(i)旗下八間甲一級護理安老院的平均每月住宿費增加;及(ii)鬆齡雅苑的入住率改善。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.